Temozolomide
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Temozolomide |
| DrugBank ID | DB00853 |
| Brand Names (EU) | Temomedac |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.36% |
Approved Indication (EMA)
Temomedac hard capsules is indicated for the treatment of: adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment; children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | adult astrocytic tumour | 99.36% | DL |
| 2 | cauda equina neoplasm | 99.30% | DL |
| 3 | astrocytoma (excluding glioblastoma) | 99.29% | DL |
| 4 | childhood cerebral astrocytoma | 97.49% | DL |
| 5 | cerebellar astrocytoma | 97.44% | DL |
| 6 | subependymal giant cell astrocytoma | 97.43% | DL |
| 7 | brain glioblastoma | 97.42% | DL |
| 8 | diencephalic astrocytomas | 97.35% | DL |
| 9 | astrocytic tumor | 97.25% | DL |
| 10 | high grade astrocytic tumor | 97.17% | DL |
| 11 | low grade astrocytic tumor | 96.48% | DL |
| 12 | brain astrocytoma | 96.31% | DL |
| 13 | childhood astrocytic tumor | 96.08% | DL |
| 14 | low-grade astrocytoma | 96.05% | DL |
| 15 | neural glioblastoma | 95.99% | DL |
| 16 | mesenchymal glioblastoma | 95.99% | DL |
| 17 | classical glioblastoma | 95.99% | DL |
| 18 | brain stem glioma | 95.88% | DL |
| 19 | adult glioblastoma | 95.83% | DL |
| 20 | ependymal tumor of brain | 95.63% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.